logo-loader

Akers Biosciences off to a “blazing start” in 2016 says chief

Last updated: 16:22 02 Mar 2016 GMT, First published: 11:22 02 Mar 2016 GMT

Ray Akers, executive chairman of Akers Biosciences (NASDAQ:AKER, LON:AKR) says the company has made a “blazing start” to the year after its Chinese distributor placed a US$2.5mln order that will be fulfilled in tranches throughout 2016.

The firm has started to supply its test for Heparin allergy or HIT into China after it was cleared for medical use in the country.

“This is the first test of any kind approved for Heparin allergy in China,” Akers says, meaning the firm is the “gold standard”.

“I think everybody is going to please with the trajectory of Akers Bio,” he adds.

Chesnara reports strong 2023 results with improved cash generation and...

Chesnara PLC (LSE:CSN) chief executive Steve Murray discusses the company's full-year results for 2023 with Proactive's Stephen Gunnion, describing them as strong and particularly highlighting £53 million in commercial cash generation and a dividend coverage of around 150%. The company has...

23 minutes ago